A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial
CS Fuchs, S Azevedo, T Okusaka, J-L Van Laethem, LR Lipton, H Riess, C Szczylik, MJ Moore, M Peeters, G Bodoky, M Ikeda, B Melichar, R Nemecek, S Ohkawa, A Swieboda-Sadlej, SA Tjulandin, E Van Cutsem, R Loberg, V Haddad, JL Gansert Show all
Annals of Oncology | OXFORD UNIV PRESS | Published : 2015
This study was supported by Amgen Inc. in collaboration with Takeda Global Research & Development Center, Inc. There were no grants or applicable grant numbers for this study.